Form 3 - Initial statement of beneficial ownership of securities:
SEC Accession No. 0001576885-25-000096
Filing Date
2025-11-10
Accepted
2025-11-10 16:46:17
Documents
4
Period of Report
2025-11-06

Document Format Files

Seq Description Document Type Size
1 FORM 3 wk-form3_1762811173.html 3  
1 FORM 3 wk-form3_1762811173.xml 3 1671
2 EX-24.1 ex241acumen-section16lim.htm EX-24.1 3959
3 ex241acumen-section16lim001.jpg GRAPHIC 192831
4 ex241acumen-section16lim002.jpg GRAPHIC 38157
  Complete submission text file 0001576885-25-000096.txt   325388
Mailing Address 1210-1220 WASHINGTON STREET SUITE 210 NEWTON MA 02465
Business Address 1210-1220 WASHINGTON STREET SUITE 210 NEWTON MA 02465 617-344-4190
Acumen Pharmaceuticals, Inc. (Issuer) CIK: 0001576885 (see all company filings)

EIN.: 364108129 | State of Incorp.: DE | Fiscal Year End: 1231
SIC: 2836 Biological Products, (No Diagnostic Substances)
(CF Office: 03 Life Sciences)

Mailing Address C/O CELGENE CORP. 86 MORRIS AVENUE SUMMIT NJ 07901
Business Address
Golumbeski George (Reporting) CIK: 0001586660 (see all company filings)

Type: 3 | Act: 34 | File No.: 001-40551 | Film No.: 251467051